Ewha Womans University Seoul Hospital Administers 'Elahere' Ovarian Cancer ADC Therapy for First Time in Asia

For Patients with FRα-Positive Platinum-Resistant Ovarian Cancer

Ewha Womans University Seoul Hospital announced on July 22 that the team of Professors Hyesung Moon, Woong Joo, and Hagyun Jang at the Department of Obstetrics and Gynecology, Gynecologic Cancer Center administered Elahere (mirvetuximab soravtansine), an antibody-drug conjugate (ADC) therapy for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, to a patient on July 20, marking the first such case in Asia.

Professors Hyesung Moon, Woong Joo, and Hagyun Jang of the Gynecologic Oncology Center at Ewha Womans University Seoul Hospital. Ewha Womans University Seoul Hospital

Elahere is an ADC therapy that targets folate receptor alpha (FRα). It is used to treat patients with FRα-positive platinum-resistant ovarian cancer. This administration marks the first time Elahere has been applied in an actual clinical setting in Asia. Platinum-resistant ovarian cancer has a high recurrence rate, and the therapeutic effects of conventional chemotherapy are often limited, resulting in continuous demand for new treatment options.

With this administration, Ewha Womans University Seoul Hospital plans to accumulate domestic clinical experience and real-world data (RWD), utilizing it to develop new treatment strategies.

The Gynecologic Cancer Center at Ewha Womans University Seoul Hospital stated, "Beginning with this administration, we will strive to accumulate clinical experience and provide patients with new treatment options."

This content was produced with the assistance of AI translation services.